EU panel supports broader approval of Pfizer's Prevenar 13

09/25/2011 | Reuters

People age 50 and older should be allowed to receive Prevenar 13, a pneumococcal vaccine by Pfizer, said the European Medicines Agency's Committee for Medicinal Products for Human Use. The vaccine is indicated for younger children in the EU and the U.S., where it is marketed as Prevnar 13. The FDA previously asked for more time to evaluate the wider use.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel, Regulatory (FDA)
CareFusion
San Diego , CA
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations